Applied Therapeutics, Inc. APLT
0.10 USD 0.00 (+0.00%)
At closeJul 2, 2026, 4:00 PM EDT
0.11 0.00 +2.04%
After hours · Jul 2, 4:00 PM ET
0.103 Day range 0.103
0.09 52-week range 1.31
- YTD
- +3.00%
- 1 year
- -81.62%
Analyst view
Consensus: buy
Buy
Price target (mean) 5.92 +5644.3% upside
Now 0.103
- Target (low)
- 1.50
- Target (mean)
- 5.92
- Target (high)
- 13.00
Ratings (0m) 6 3 buy · 3 hold · 0 sell
- Strong buy0
- Buy3
- Hold3
- Sell0
- Strong sell0
Recommendation trend
- This month 6
- 1 month ago 6
- 2 months ago 6
- 3 months ago 6
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.19413 | -0.26571 – -0.13 | -0.33 | +41.2% | 100.00K | -99.0% | 5 |
| Next quarter | -0.16327 | -0.17 – -0.15981 | -0.67 | +75.6% | 12.32M | +6382.5% | 3 |
| Current year | -1.42 | -1.79 – -1.23 | -1.42 | -0.1% | 533.60K | -94.7% | 5 |
| Next year | -0.48006 | -0.71 – -0.04567 | -1.42 | +66.2% | 15.46M | +2797.8% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | William Blair | Downgrade | Outperform | Market Perform |
| Dec 20, 2024 | RBC Capital | Maintained | Sector Perform | Sector Perform |
| Dec 2, 2024 | UBS | Downgrade | Buy | Neutral |
| Nov 29, 2024 | Citigroup | Maintained | Buy | Buy |
| Nov 29, 2024 | Baird | Maintained | Outperform | Outperform |
| Nov 29, 2024 | RBC Capital | Downgrade | Outperform | Sector Perform |
| Nov 27, 2024 | Citigroup | Maintained | Buy | Buy |
| Sep 19, 2024 | Citigroup | Maintained | Buy | Buy |
| Sep 19, 2024 | Leerink Partners | Maintained | Outperform | Outperform |
| Aug 27, 2024 | Citigroup | Maintained | Buy | Buy |
| Jul 31, 2024 | William Blair | Initiated | — | Outperform |
| Jul 17, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Apr 11, 2024 | RBC Capital | Reiterated | Outperform | Outperform |
| Mar 26, 2024 | RBC Capital | Initiated | — | Outperform |
| Mar 15, 2024 | UBS | Maintained | Buy | Buy |
| Mar 6, 2024 | UBS | Maintained | Buy | Buy |
| Feb 22, 2024 | Leerink Partners | Initiated | — | Outperform |
| Feb 16, 2024 | Citigroup | Maintained | Buy | Buy |
| Apr 25, 2023 | Baird | Maintained | — | Outperform |
| Apr 5, 2023 | Citigroup | Maintained | — | Buy |
| Aug 17, 2022 | Citigroup | Maintained | — | Buy |
| Aug 16, 2022 | Barclays | Maintained | — | Equal-Weight |
| May 20, 2022 | Citigroup | Maintained | — | Buy |
| Mar 21, 2022 | Barclays | Maintained | — | Equal-Weight |
| Jan 4, 2022 | Barclays | Downgrade | Overweight | Equal-Weight |
| Aug 27, 2021 | Goldman Sachs | Downgrade | Neutral | Sell |
| Oct 8, 2020 | Truist Securities | Initiated | — | Buy |
| Feb 27, 2020 | Barclays | Initiated | — | Overweight |
| Jan 9, 2020 | Citigroup | Maintained | — | Buy |
| Jan 8, 2020 | Baird | Maintained | — | Outperform |